Balasa Dinverno & Foltz’s Regeneron Pharmaceuticals REGN Stock Holding History

Balasa Dinverno & Foltz’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.25M	Buy	1,822 +135	+8%	+$85K	0.08%	101
2022 Q2	$997K	Sell	1,687 -86	-5%	-$55.9K	0.06%	131
2022 Q1	$1.24M	Buy	1,773 +393	+28%	+$249K	0.08%	112
2021 Q4	$871K	Buy	1,380 +617	+81%	+$379K	0.06%	144
2021 Q3	$462K	Buy	763 +212	+38%	+$132K	0.03%	200
2021 Q2	$308K	Sell	551 -91	-14%	-$46.1K	0.02%	254
2021 Q1	$304K	Sell	642 -1,011	-61%	-$492K	0.02%	236
2020 Q4	$799K	Sell	1,653 -850	-34%	-$459K	0.07%	125
2020 Q3	$1.4M	Sell	2,503 -18	-0.7%	-$10.9K	0.13%	73
2020 Q2	$1.57M	Buy	2,521 +2,019	+402%	+$1.15M	0.17%	57
2020 Q1	$245K	Buy	+502	New	+$207K	0.03%	212

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Balasa Dinverno & Foltz's REGN Position: Q3 2022 in Review

Balasa Dinverno & Foltz increased its Regeneron Pharmaceuticals (REGN) stake by 8% in Q3 2022, buying an estimated $85K and bringing the position to 1,822 shares worth $1.25M. The position accounts for 0.08% of the portfolio, ranked #101.

Balasa Dinverno & Foltz first reported a position in REGN in Q1 2020 and has held it in 11 quarters since. The position peaked at $1.57M in Q2 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Balasa Dinverno & Foltz held 1,822 shares of Regeneron Pharmaceuticals worth $1.25M as of Q3 2022.
Balasa Dinverno & Foltz bought 135 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $85K.
Regeneron Pharmaceuticals made up 0.08% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #101 holding.
Balasa Dinverno & Foltz first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 11 quarters since.
Balasa Dinverno & Foltz's Regeneron Pharmaceuticals position peaked at $1.57M in Q2 2020.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.